Bystander cells and prognosis in Hodgkin lymphoma

Upsala Journal of Medical Sciences

Volumn 109, Issue 3, 2004, Pages 179-228

  Molin, Daniel ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; EOSINOPHIL CATIONIC PROTEIN; PREDNISONE; PROCARBAZINE; TRYPTASE; VINCRISTINE;

ADULT; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CELL INFILTRATION; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENETIC POLYMORPHISM; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOELECTRIC POINT; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MAST CELL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR REGRESSION;

EID: 5144232042     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/2000-1967-084     Document Type: Review

References (301)

1. Hodgkin T (1832). On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 17: 68-114.
2. Mauch P, Armitage, JO, Diehl, V, Hoppe, RT, Weiss, LM (Eds.).: Hodgkin's disease. Philadelphia, Lippincott Williams & Wilkins, 1999.
3. Rosenfeld L (2000). Thomas Hodgkin: social activist. Ann Diagn Pathol 4: 124-33.
4. Malpighi M: In De viscerum structura exercitatio anatomica. Amstelodami, 1669.
5. Fox H (1926). Remarks on microscopical preparations made from some of the original tissue described by Thomas Hodgkin, 1832. Ann Med Hist 8: 370-374.
6. Dawson P (1968). The original illustrations of Hodgkin's disease. Arch Int Med 121: 288-290.
7. Wilks SS (1865). Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease) with remarks. Guy's Hosp Rep 11: 56-67.
8. Greenfield W (1878). Specimens illustrative of the pathology of lymphadenoma and leucocythaemia. Transactions of the Pathological Society of London 29: 272-304.
9. Jaffe ES HN, Stein H, Vardiman JW (Eds.).: World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press, 2001.
10. Sternberg C (1898). Uber eine eigenartige unter dem Bilde der Pseudoleukämie verlaufende Tuberculose des lymphatischen Apparates. Ztchr Heilk 19: 21-90.
11. Reed D (1902). On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkin's Hospital Reports 10: 133-196.
12. Rosenthal S (1936). Significance of tissue lymphocytes in the prognosis of lymphogranulomatosis. Arch Pathol Lab Med 21: 628-646.
13. Jackson H PF: Hodgkin's disease and allied disorders. New York, Oxford University Press, 1947
14. Smetana HF CB (1956). Mortality in relation to histologic type in Hodgkin's disease. Blood 11: 211-224.
15. Lukes RJ BJ, Hicks EB (1966). Natural history of Hodgkin's disease as related to its pathological picture. Cancer 19: 317-344.
16. Lukes RJ CL, Hall TC, et al (1966). Report of the nomenclature committee. Cancer Res 26: 1311
17. Lukes R, Butler JJ (1966). The pathology and nomenclature of Hodgkin's disease. Cancer Res 26: 1063-1081.
18. Harris N, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. Related Articles (1994). A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.
19. Kant JA, Hubbard SM, Longo DL, Simon RM, DeVita VT, Jr., Jaffe ES (1986). The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease. J Clin Oncol 4: 284-94.
20. Amini R: Hodgkin lymphoma. Studies of advanced stages, relapses and the relation to non-hodgkin lymphomas., in Department of Oncology, Radiology, and Clinical Immunology. Uppsala, Uppsala University, 2002, p 64.
21. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, Hansmann ML (1994). Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 91: 10962-6.
22. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K (1996). Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184: 1495-505.
23. Kuppers R, Schwering I, Brauninger A, Rajewsky K, Hansmann ML (2002). Biology of Hodgkin's lymphoma. Ann Oncol 13: 11-8.
24. Seitz V, Hummel M, Marafioti T, Anagnostopoulos I, Assaf C, Stein H (2000). Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95: 3020-4.
25. Muschen M, Rajewsky K, Brauninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Kuppers R (2000). Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 191: 387-94.
26. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I, Wirth T, Demel G, Falini B (2001). Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97: 496-501.
27. Torlakovic E, Tierens A, Dang HD, Delabie J (2001). The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 159: 1807-14.
28. Lam KP, Kuhn R, Rajewsky K (1997). In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90: 1073-83.
29. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer HD, Scheidereit C, Dorken B (1996). High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87: 4340-7.
30. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B (1997). Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100: 2961-9.
31. Jungnickel B, Staratschek-Jox A, Brauninger A, Spieker T, Wolf J, Diehl V, Hansmann ML, Rajewsky K, Kuppers R (2000). Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 191: 395-402.
32. Durkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H (1999). Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus- transformed lymphoid cells. Blood 93: 617-23.
33. Annunziata CM, Safiran YJ, Irving SG, Kasid UN, Cossman J (2000). Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor. Blood 96: 2841-8.
34. Feuillard J, Schuhmacher M, Kohanna S, Asso-Bonnet M, Ledeur F, Joubert-Caron R, Bissieres P, Polack A, Bornkamm GW, Raphael M (2000). Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. Blood 95: 2068-75.
35. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (1997). Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 272: 2042-5.
36. Horie R, Aizawa S, Nagai M, Ito K, Higashihara M, Ishida T, Inoue J, Watanabe T (1998). A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. Int Immunol 10: 203-10.
37. Zander T, Wiedenmann S, Wolf J (2002). Prognostic factors in Hodgkin's lymphoma. Ann Oncol 13: 67-74.
38. Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Improta S, Juzbasic S, Todesco M, Perin V, Gattei V, Herrmann F, Gruss HJ, Carbone A. (1996). Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 88: 3299-305.
39. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, et al. (1994). Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12: 793-7.
40. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V (1982). Production of a monoclonal antibody specific for Hodgkin and Sternberg- Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299: 65-7.
41. Re D, Hofmann A, Wolf J, Diehl V, Staratschek-Jox A (2000). Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 28: 348.
42. Poppema S, van den Berg A (2000). Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 10: 345-50.
43. van Spronsen DJ, Peh SC, Vrints LW, van Imhoff GW, Poppema S (2000). Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology 37: 420-6.
44. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, Fraga M, Garcia-Del-Moral R, Gomez-Marcos F, Menarguez J, Oliva H, Sanchez-Beato M, Montalban C (1997). Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 90: 2429-36.
45. Thomas RK KA, Wickenhauser C, Schultze JL, Draube A, Vockerodt M, Re D, Diehl V, Wolf J.: C-Flip is constitutively expressed by Hodgkin and Reed-Sternberg cells (Abstract 35), in Eight International Conference on Mallignant Lymphoma. Lugano, Ann Oncol, 2002, p 11.
46. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S (2002). Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 13: 52-6.
47. Samoszuk M, Nansen L (1990). Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 75: 13-6.
48. Klein S, Jucker M, Diehl V, Tesch H (1992). Production of multiple cytokines by Hodgkin's disease derived cell lines. Hematol Oncol 10: 319-29.
49. Merz H, Houssiau FA, Orscheschek K, Renauld JC, Fliedner A, Herin M, Noel H, Kadin M, Mueller-Hermelink HK, Van Snick J, et al. (1991). Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 78: 1311-7.
50. Gruss HJ, Brach MA, Drexler HG, Bross KJ, Herrmann F (1992). Interleukin 9 is expressed by primary and cultured Hodgkin and Reed- Sternberg cells. Cancer Res 52: 1026-31.
51. Renauld JC, Kermouni A, Vink A, Louahed J, Van Snick J (1995). Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. Journal of leukocyte biology 57: 353.
52. Nilsson G, Nilsson K (1995). Effects of interleukin (IL)-13 on immediate-early response gene expression, phenotype and differentiation of human mast cells. Comparison with IL-4. Eur J Immunol 25: 870-3.
53. Hsu SM, Xie SS, Hsu PL, Waldron JA, Jr. (1992). Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease. Am J Pathol 141: 129-38.
54. Foss HD, Hummel M, Gottstein S, Ziemann K, Falini B, Herbst H, Stein H (1995). Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease. Am J Pathol 146: 33-9.
55. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H, Agathanggelou A, Niedobitek G, Stein H (1996). Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 87: 2918-29.
56. Hsu SM, Lin J, Xie SS, Hsu PL, Rich S (1993). Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol 24: 249-55.
57. Kadin ME, Agnarsson BA, Ellingsworth LR, Newcom SR (1990). Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am J Pathol 136: 1209-14.
58. Tedla N, Palladinetti P, Wakefield D, Lloyd A (1999). Abundant expression of chemokines in malignant and infective human lymphadenopathies. Cytokine 11: 531-40.
59. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G. (1999). Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 93(8): 2463-70.
60. Fischer M, Juremalm M, Olsson N, Backlin C, Enblad G, Nilsson G. (2001). Expression of RANTES in Hodgkin's disease, a possible explanation for mast cell infiltration. (Abstract P-025). Leukemia and lymphoma 42 (Suppl 2): 31.
61. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Muller G, Foss HD, Royer HD, Stein H, Dorken B. (1999). Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 94(6): 2065-71.
62. van den Berg A, Visser L, Poppema S (1999). High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 154: 1685-91.
63. Toth J, Dworak O, Sugar J. (1977). Eosinophil predominance in Hodgkin's disease. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 89(1): 107-11.
64. Enblad G, Sundstrom C, Glimelius B. (1993). Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol. 11: 187-93.
65. Crocker J, Smith PJ (1984). A quantitative study of mast cells in Hodgkin's disease. J Clin Pathol 37: 519-22.
66. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000). The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J 1: 53-66.
67. Ohshima K, Tutiya T, Yamaguchi T, Suzuki K, Suzumiya J, Kawasaki C, Haraoka S, Kikuchi M (2002). Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer 98: 567-72.
68. Skinnider BF, Mak TW (2002). The role of cytokines in classical Hodgkin lymphoma. Blood 99: 4283-97.
69. Gruss HJ, Pinto A, Gloghini A, Wehnes E, Wright B, Boiani N, Aldinucci D, Gattei V, Zagonel V, Smith CA, Kadin ME, von Schilling C, Goodwin RG, Herrmann F, Carbone A (1996). CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 149: 469-81.
70. Wong DT, Elovic A, Matossian K, Nagura N, McBride J, Chou MY, Gordon JR, Rand TH, Galli SJ, Weller PF (1991). Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood 78: 2702-7.
71. Homeros Odysséen.
72. Homeros: Iliaden.
73. Byström J: Eosinophil cationic protein. Expression levels and polymorphisms., in Department of Medical Sciences. Uppsala, Uppsala University, 2002.
74. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML, Diehl V, Georgii A (2000). Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 95: 1207-13.
75. Axdorph U, Porwit-MacDonald A, Grimfors G, Bjorkholm M (2001). Tissue eosinophilia in relation to immunopathological and clinical characteristics in Hodgkin's disease. Leuk Lymphoma 42: 1055-65.
76. Macintyre EA, Vaughan Hudson B, Vaughan Hudson G, Jelliffe AM, Linch DC (1987). Incidence and clinical importance of bone marrow eosinophilia in Hodgkin's disease (BNLI Report No 29). British National Lymphoma Investigation. J Clin Pathol 40: 245-6.
77. Vaughan Hudson B, Linch DC, Macintyre EA, Bennett MH, MacLennan KA, Vaughan Hudson G, Jelliffe AM (1987). Selective peripheral blood eosinophilia associated with survival advantage in Hodgkin's disease (BNLI Report No 31). British National Lymphoma Investigation. J Clin Pathol 40: 247-50.
78. Desenne JJ, Acquatella G, Stern R, Muller A, Sanchez M, Somoza R (1992). Blood eosinophilia in Hodgkin's disease. A follow-up of 25 cases in Venezuela. Cancer 69: 1248-53.
79. Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG, 2nd, Kimball PM, Boohaker EA (1983). Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43: 2997-3000.
80. Goldsmith MM, Belchis DA, Cresson DH, Merritt WD, 3rd, Askin FB (1992). The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 106: 27-33.
81. Endo M UK, Kitazume K, Iwabe K, Okuyama Y, Urabe A. (1995). Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte- macrophage colony-stimulating factor. Ann Hematol 71: 313.
82. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG (1994). Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83: 2045-56.
83. Newcom S, Tagra KK. (1992). High molecular weight transforming growth factor beta is excreted in the urine in active nodular sclerosing Hodgkin's disease. Cancer Res 52(24): 6768-73.
84. Kadin M, Butmarc J, Elovic A, Wong D. (1993). Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease. Am J Pathol 142(1): 11-6.
85. Hernäs J, Särnstrand B, Lindroth P, Peterson CGP, Venge P, Malmström A (1992). Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol 59: 352.
86. DeChatelet LR, Migler RA, Shirley PS, Muss HB, Szejda P, Bass DA (1978). Comparison of intracellular bactericidal activities of human neutrophils and eosinophils. Blood 52: 609-17.
87. Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL (1990). In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol 144: 3166-73.
88. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF (1998). Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res 26: 3358-63.
89. Trulson A, Nilsson S, Venge P (1997). The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol 98: 312-4.
90. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulson A (1999). Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 29: 1172-86.
91. Lewis DM, Lewis JC, Loegering DA, Gleich GJ (1978). Localization of the guinea pig eosinophil major basic protein to the core of the granule. J Cell Biol 77: 702-13.
92. Peterson CG, Venge P (1983). Purification and characterization of a new cationic protein - eosinophil protein-X (EPX) - from granules of human eosinophils. Immunology 50: 19-26.
93. Wever R, Hamers MN, Weening RS, Roos D (1980). Characterization of the peroxidase in human eosinophils. Eur J Biochem 108: 491-5.
94. Olsson I, Venge P, Spitznagel JK, Lehrer RI (1977). Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Lab Invest 36: 493-500.
95. Levi-Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M, Hohenstein R, Barak V, Lacy P, Kay AB, Moqbel R (1996). Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 87: 155-61.
96. Moller GM, de Jong TA, Overbeek SE, van der Kwast TH, Postma DS, Hoogsteden HC (1996). Ultrastructural immunogold localization of interleukin 5 to the crystalloid core compartment of eosinophil secondary granules in patients with atopic asthma. J Histochem Cytochem 44: 67-9.
97. Iozzo RV, MacDonald GH, Wight TN (1982). Immunoelectron microscopic localization of catalase in human eosinophilic leukocytes. J Histochem Cytochem 30: 697-701.
98. Hamid Q, Barkans J, Meng Q, Ying S, Abrams JS, Kay AB, Moqbel R (1992). Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 80: 1496-501.
99. Beil WJ, Weller PF, Tzizik DM, Galli SJ, Dvorak AM (1993). Ultrastructural immunogold localization of tumor necrosis factor-alpha to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypereosinophilic syndrome. J Histochem Cytochem 41: 1611-5.
100. Ying S, Meng Q, Taborda-Barata L, Corrigan CJ, Barkans J, Assoufi B, Moqbel R, Durham SR, Kay AB (1996). Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur J Immunol 26: 70-6.
101. Calafat J, Janssen H, Tool A, Dentener MA, Knol EF, Rosenberg HF, Egesten A (1998). The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils. Blood 91: 4770-5.
102. Levi-Schaffer F, Weg VB (1997). Mast cells, eosinophils and fibrosis. Clin Exp Allergy 27 Suppl 1: 64-70.
103. Tsuyuki S, Bertrand C, Erard F, Trifilieff A, Tsuyuki J, Wesp M, Anderson GP, Coyle AJ (1995). Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J Clin Invest 96: 2924-31.
104. Peterson CG, Jornvall H, Venge P (1988). Purification and characterization of eosinophil cationic protein from normal human eosinophils. Eur J Haematol 40: 415-23.
105. Slifman NR, Loegering DA, McKean DJ, Gleich GJ (1986). Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 137: 2913-7.
106. Gullberg U, Widegren B, Arnason U, Egesten A, Olsson I (1986). The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity. Biochem Biophys Res Commun 139: 1239-42.
107. Young JD, Peterson CG, Venge P, Cohn ZA (1986). Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321: 613-6.
108. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ (1989). Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 142: 4428-34.
109. Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL (1984). Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 133: 2180-5.
110. Patella V, de Crescenzo G, Marino I, Genovese A, Adt M, Gleich GJ, Marone G (1996). Eosinophil granule proteins activate human heart mast cells. J Immunol 157: 1219-25.
111. Okayama Y, el-Lati SG, Leiferman KM, Church MK (1994). Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells. J Allergy Clin Immunol 93: 900-9.
112. Venge P, Dahl R, Hallgren R (1979). Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res 14: 641-9.
113. Kimata H, Yoshida A, Ishioka C, Jiang Y, Mikawa H (1992). Inhibition of ongoing immunoglobulin production by eosinophil cationic protein. Clin Immunol Immunopathol 64: 84-8.
114. Kimata H, Yoshida A, Ishioka C, Jiang Y, Mikawa H (1992). Eosinophil cationic protein inhibits immunoglobulin production and proliferation in vitro in human plasma cells. Cell Immunol 141: 422-32.
115. Ehrlich P: Beiträge zur Theorie und Praxis der Histologischen Färbung. Leipzig, Univ of Leipzig, 1878.
116. Sundström M: Signal transduction in mast cell migration, in Department of Genetics and Pathology. Uppsala, University of Uppsala, 2001.
117. Arock M, Ross E, Lai-Kuen R, Averlant G, Gao Z, Abraham SN (1998). Phagocytic and tumor necrosis factor alpha response of human mast cells following exposure to gram-negative and gram-positive bacteria. Infect Immun 66: 6030-4.
118. Galli SJ, Wershil BK (1996). The two faces of the mast cell. Nature 381: 21-2.
119. Metcalfe DD, Baram D, Mekori YA (1997). Mast cells. Physiol Rev 77: 1033-79.
120. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C (1997). Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 99: 1492-9.
121. Mekori YA, Metcalfe DD (2000). Mast cells in innate immunity. Immunol Rev 173: 131-40.
122. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382-97.
123. Zhang Y, Ramos BF, Jakschik BA (1992). Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 258: 1957-9.
124. Roupe G (2002). Mastocytosis - two diseases with different pathophysiology. Lakartidningen 99: 2400-4.
125. Dimitriadou V, Koutsilieris M (1997). Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res 17: 1541-9.
126. Sharma VK, Agrawal A, Pratap VK, Nagar AM, Mehrotra ML (1992). Mast cell reactivity in lymphoma: a preliminary communication. Indian J Cancer 29: 61-5.
127. Dethlefsen SM, Matsuura N, Zetter BR (1994). Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Invasion Metastasis 14: 395-408.
128. Roche WR (1985). Mast cells and tumors. The specific enhancement of tumor proliferation in vitro. Am J Pathol 119: 57-64.
129. Feiner AS, Mahmood T, Wallner SF (1978). Prognostic importance of pruritus in Hodgkin's disease. Jama 240: 2738-40.
130. Gobbi PG, Cavalli C, Gendarini A, Crema A, Ricevuti G, Federico M, Di Prisco U, Ascari E (1985). Reevaluation of prognostic significance of symptoms in Hodgkin's disease. Cancer 56: 2874-80.
131. Bichel J (1972). Is the alcohol-intolerance syndrome in Hodgkin's disease disappearing? Lancet 1: 1069.
132. Mauch PM AJ, Diehl V, Hoppe RT, Weiss LM (Editors): Hodgkin's disease. Philadelphia, Lippincott, Williams & Wilkins, 1999.
133. Custodi P, Cerutti A, Bagnato R, Cassani P (1993). Alcohol-induced pain in tuberculous adenitis. Haematologica 78: 416-7.
134. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES (1999). Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22: 231-8.
135. Encyclopædia Britannica (2002). Hardy-Weinberg equilibrium "Hardy 〈http://search.eb.com/eb/article?eu=40058〉. July 19:
136. Paz-y-Mino C, Perez JC, Fiallo BF, Leone PE (2002). A polymorphism in the hMSH2 gene (gIVS12-6T>C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet 133: 29-33.
137. Dieckvoss BO, Stanulla M, Schrappe M, Beier R, Zimmermann M, Weite K, Reiter A (2002). Polymorphisms within glutathione S-transferase genes in pediatric non- Hodgkin's lymphoma. Haematologica 87: 709-13.
138. Libura J, Bettens F, Radkowski A, Tiercy JM, Piguet PF (2002). Polymorphic tumor necrosis factors microsatellite TNFa4 is associated with resistance of Hodgkin lymphoma to chemotherapy and with replapses after therapy. Anticancer Res 22: 921-6.
139. MacMahon B (1966). Epidemiology of Hodgkin's disease. Cancer Res 26: 1189-201.
140. Correa P, O'Conor GT (1971). Epidemiologic patterns of Hodgkin's disease. Int J Cancer 8: 192-201.
141. Franssila KO, Heiskala MK, Heiskala HJ (1977). Epidemiology and histopathology of Hodgkin's disease in Finland. Cancer 39: 1280-8.
142. Hartge P, Devesa SS, Fraumeni JF, Jr. (1994). Hodgkin's and non-Hodgkin's lymphomas. Cancer Surv 20: 423-53.
143. Merk K, Bjorkholm M, Rengifo E, Gavilondo J, Holm G, Rivas H (1990). Epidemiological study of Hodgkin's disease in Cuba and Sweden. Oncology 47: 246-50.
144. Foss Abrahamsen A, Egeland T, Hansen S, Langholm R, Holte H, Kvaloy S (1997). Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer 33: 2380-3.
145. Liu S, Semenciw R, Waters C, Wen SW, Mao Y (2000). Time trends and sex patterns in Hodgkin's disease incidence in Canada, 1970-1995. Can J Public Health 91: 188-92.
146. Hjalgrim H, Askling J, Pukkala E, Hansen S, Munksgaard L, Frisch M (2001). Incidence of Hodgkin's disease in Nordic countries. Lancet 358: 297-8.
147. Gutensohn NM (1982). Social class and age at diagnosis of Hodgkin's disease: new epidemiologic evidence for the "two-disease hypothesis". Cancer Treat Rep 66: 689-95.
148. Grufferman S, Cole P, Smith PG, Lukes RJ (1977). Hodgkin's disease in siblings. N Engl J Med 296: 248-250.
149. Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM, Taylor CR, Hamilton AS, Deapen DM, Rappaport EB (1995). Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 332: 413-8.
150. Wolf J, Diehl V (1994). Is Hodgkin's disease an infectious disease? Ann Oncol 5: 105-11.
151. Glaser SL, Jarrett RF (1996). The epidemiology of Hodgkin's disease. Baillieres Clin Haematol 9: 401-16.
152. Hjalgrim H, Askling J, Sorensen P, Madsen M, Rosdahl N, Storm HH, Hamilton-Dutoit S, Eriksen LS, Frisch M, Ekbom A, Melbye M (2000). Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 92: 1522-8.
153. Gutensohn N, Cole P (1980). Epidemiology of Hodgkin's disease. Semin Oncol 7: 92-102.
154. Khan G, Norton AJ, Slavin G (1993). Epstein-Barr virus in Hodgkin disease. Relation to age and subtype. Cancer 71: 3124-9.
155. Enblad G, Sandvej K, Sundstrom C, Pallesen G, Glimelius B (1999). Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncol 38: 425-9.
156. Gulley ML, Eagan PA, Quintanilla-Martinez L, Picado AL, Smir BN, Childs C, Dunn CD, Craig FE, Williams JW, Jr., Banks PM (1994). Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood 83: 1595-602.
157. Harper PG, Fisher C, McLennan K, Souhami RL (1984). Presentation of Hodgkin's disease as an endobronchial lesion. Cancer 53: 147-50.
158. Grimfors G, Holm G, Mellstedt H, Schnell PO, Tullgren O, Bjorkholm M (1990). Increased blood clearance rate of indium-111 oxine-labeled autologous CD4+ blood cells in untreated patients with Hodgkin's disease. Blood 76: 583-9.
159. Merk K, Bjorkholm M, Tullgren O, Mellstedt H, Holm G (1990). Immune deficiency in family members of patients with Hodgkin's disease. Cancer 66: 1938-43.
160. Dolcetti R, Frisan T, Sjoberg J, De Campos-Lima PO, Pisa P, De Re V, Gloghini A, Rizzo S, Masucci MG, Boiocchi M (1995). Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. Cancer Res 55: 3675-81.
161. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, et al. (1995). Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86: 1493-501.
162. Axdorph U, Sjoberg J, Grimfors G, Landgren O, Porwit-MacDonald A, Bjorkholm M (2000). Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol 11: 1405-11.
163. Rooney C GB, Bollard C, Huls H, Brenner M, Heslop H. (2001). Prospects for the immunotherapy of EBV+ Hodgkin disease using EBV-specific CTLs. (Abstract I-16). Leukemia & Lymphoma 42: 7.
164. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971). Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31: 1860-1.
165. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7: 1630-6.
166. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, Textoris F, Ansen S, Franklin J, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H (2002). Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 81: 20-5.
167. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G (2001). Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86: 266-73.
168. Lang O, Bihl H, Hultenschmidt B, Sautter-Bihl ML (2001). Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease. Strahlenther Onkol 177: 138-44.
169. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK
170. Mikhaeel N, Mainwaring, P, Nunan, T, Timothy, AR. (2002). Prognostic value of interim and post-treatment FDG-PET scanning in Hodgkin Lymphoma. (Abstract 063). Ann Oncol 13 (2): 21
171. Aisenberg AC (1999). Problems in Hodgkin's disease management. Blood 93: 761-79.
172. Josting A, Diehl V (2001). Early-stage Hodgkin's disease. Curr Oncol Rep 3: 279-84.
173. Longo DL, Glatstein E, Duffey PL, Young RC, Hubbard SM, Urba WJ, Wesley MN, Raubitschek A, Jaffe ES, Wiernik PH, et al. (1991). Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J Clin Oncol 9: 906-17.
174. Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V (2002). Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 20: 476-84.
175. Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI (2001). Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19: 4238-44.
176. Hasenclever D (2002). The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 13: 75-8.
177. Glimelius B, Enblad G, Kalkner M, Gustavsson A, Jakobsson M, Branehog I, Lenner P, Bjorkholm M (1996). Treatment of Hodgkin's disease: the Swedish National Care Programme experience. Leuk Lymphoma 21: 71-8.
178. Peters MV (1971). Summary of informal discussion on the prognostic and therapeutic implications of staging in Hodgkin's disease. Cancer Res 31: 1851-3.
179. Aisenberg AC, Qazi R (1976). Improved survival in hodgkin's disease. Cancer 37: 2423-9.
180. Bjorkholm M, Holm G, Mellstedt H, Johansson B, Askergren J, Soderberg G (1977). Prognostic factors in Hodgkin's disease. I. Analysis of histopathology, stage distribution and results of therapy. Scand J Haematol 19: 487-95.
181. Mauch P, Goodman R, Hellman S (1978). The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 42: 1039-45.
182. Prosnitz LR, Curtis AM, Knowlton AH, Peters LM, Farber LR (1980). Supradiaphragmatic Hodgkin's disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 6: 809-13.
183. Mazza P, Lauria F, Sciascia R, Emiliani E, Fiacchini M, Baccarani M, Frezza G, Dominici G, Cantore M, Faedi M, et al. (1983). Prognostic significance of large mediastinal involvement in Hodgkin's disease. Scand J Haematol 31: 315-21.
184. Liew KH, Easton D, Horwich A, Barrett A, Peckham MJ (1984). Bulky mediastinal Hodgkin's disease management and prognosis. Hematol Oncol 2: 45-59.
185. Horwich A, Easton D, Nogueira-Costa R, Liew KH, Colman M, Peckham MJ (1986). An analysis of prognostic factors in early stage Hodgkin's disease. Radiother Oncol 7: 95-106.
186. Anderson H, Deakin DP, Wagstaff J, Jones JM, Todd ID, Wilkinson PM, James RD, Steward WP, Blackledge G, Scarffe JH, et al. (1984). A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group. Br J Cancer 49: 695-702.
187. Cimino G, Biti GP, Anselmo AP, Maurizi Enrici R, Bellesi GP, Bosi A, Cionini L, Mungai V, Papa G, Ponticelli P, et al. (1989). MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease. J Clin Oncol 7: 732-7.
188. Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM (1987). Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 5: 1041-9.
189. Tarbell NJ, Thompson L, Mauch P (1990). Thoracic irradiation in Hodgkin's disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 18: 275-81.
190. Mauch P, Gorshein D, Cunningham J, Hellman S (1982). Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat Rep 66: 809-17.
191. Lee CK, Bloomfield CD, Goldman AI, Levitt SH (1980). Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 46: 2403-9.
192. Rodgers RW, Fuller LM, Hagemeister FB, Johnston DA, Sullivan JA, North LB, Butler JJ, Velasquez WS, Conrad FG, Shullenberger CC (1981). Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy. Cancer 47: 2196-203.
193. Bonadonna G, Valagussa P, Santoro A (1985). Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv 4: 439-58.
194. Specht L, Lauritzen AF, Nordentoft AM, Andersen PK, Christensen BE, Hippe E, Hou-Jensen K, Nissen NI. (1990). Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group. Cancer 65(11): 2594-601.
195. Specht L (1992). Tumour burden as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer 12: 1982-5.
196. Specht L (1992). Prognostic factors in Hodgkin's disease. Dan Med Bull 39: 409-22.
197. Gobbi P, Broglia, C, Di Giulio, G, Garioni, L, Anselmo, AP, Zinzani, PL, Merli, F, Berte, R, Levis, A, Nadali, G.: The directly measurable tumour burden (TB) is the main prognosticator in Hodgkin's lymphoma. Abstract 203., in Eight International Conference on Malignant Lymphoma. Lugano, Ann Oncol, 2002, p 62.
198. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G (1998). Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood 91: 3011-6.
199. Christiansen I, Enblad G, Kalkner KM, Gidlof C, Glimelius B, Totterman TH (1995). Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival. Leuk Lymphoma 19: 243-51.
200. Enblad G AR, Sundström C, Glimelius B. (1997). Serum levels of soluble CD30 and their relationship to tumour burden and prognosis in patients with Hodgkin's disease. Haematol. 2: 113-123.
201. Dukers DF, Meijer CJ, ten Berge RL, Vos W, Ossenkoppele GJ, Oudejans JJ (2002). High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. Blood 100: 36-42.
202. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarkson BD (1990). Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8: 1173-86.
203. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT, Jr. (1986). Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4: 1295-306.
204. Bartl R, Frisch B, Burkhardt R, Huhn D, Pappenberger R (1982). Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors. Br J Haematol 51: 345-60.
205. Specht L, Nissen NI (1988). Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 41: 359-67.
206. Haybittle JL, Hayhoe FG, Easterling MJ, Jelliffe AM, Bennett MH, Vaughan Hudson G, Vaughan Hudson B, MacLennan KA (1985). Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1: 967-72.
207. MacLennan KA, Bennett MH, Tu A, Hudson BV, Easterling MJ, Hudson GV, Jelliffe AM (1989). Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 64: 1686-93.
208. Hess JL, Bodis S, Pinkus G, Silver B, Mauch P (1994). Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 74: 708-14.
209. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, Kluin PM, Kluin-Nelemans JC, van Diest PJ, Middeldorp JM, Meijer CJ (1997). Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 89: 1376-82.
210. Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982). The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59: 455-65.
211. Loffler M, Mauch P, MacLennan K, Specht L, Henry-Amar M (1992). The Second International Symposium on Hodgkin's Disease. Workshop I: Review on prognostic factors. Ann Oncol 3 Suppl 4: 63-6.
212. Tubiana M, Attie E, Flamant R, Gerard-Marchant R, Hayat M (1971). Prognostic factors in 454 cases of Hodgkin's disease. Cancer Res 31: 1801-10.
213. Hasenclever D, Diehl V (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339: 1506-14.
214. Proctor SJ, Taylor P, Mackie MJ, Donnan P, Boys R, Lennard A, Prescott RJ (1992). A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Leuk Lymphoma 7: 17-20.
215. Christiansen I, Sundstrom C, Enblad G, Totterman TH (1998). Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease. Br J Haematol 102: 701-9.
216. Peters V (1950). A study of survivals in Hodgkin's disease treated radiologically. Am J of Roentgenol 63: 299-311.
217. Tullgren O, Grimfors G, Holm G, Johansson B, Svedmyr E, Wedelin C, Mellstedt H, Merk K, Bjorkholm M (1991). Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-up. Cancer 68: 768-75.
218. Proctor SJ, Taylor P, Donnan P, Boys R, Lennard A, Prescott RJ (1991). A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 27: 624-9.
219. Proctor SJ, Mackie M, Dawson A, White J, Prescott RJ, Lucraft HL, Angus B, Jackson GH, Lennard AL, Hepplestone A, Taylor PR (2002). A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer 38: 795-806.
220. Josting A, Wolf J, Diehl V (2000). Hodgkin disease: prognostic factors and treatment strategies. Curr Opin Oncol 12: 403-11.
221. Pusey W (1902). Cases of sarcoma of Hodgkin's disease treated by exposures to x-rays: a preliminary report. JAMA 38: 166-169.
222. Gilbert R, Babaintz L. (1931). Notre méthode de roentgentherapie de la lymphogranulomatose (Hodgkin). Acta Radiol 12: 523.
223. Kaplan H (1962). The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 78: 553-561.
224. DeVita V, Serpick, A. (1967). Combination chemotherapy in the treatment of advanced Hodgkin's disease. (Abstract). Proc Am Assoc Cancer Res 8: 13.
225. DeVita V, Serpick, AA, Carbone, P. (1970). Combination chemotherapy in the treatment of advanced stages Hodgkin's disease. Ann Intern Med 73: 881-895.
226. DeVita V, Simon, RM, Hubbard, SM, Young, RC, Berard, CW, Moxley, JH 3rd et al. (1980). Curability of advanced Hodgkin's disease with chemotherapy: Long term follow-up of MOPP treated patients at the National Cancer Institute. Ann Intern Med 92: 587-595.
227. Glimelius B, Kalkner M, Enblad G, Gustavsson A, Jakobsson M, Branehog I, Lenner P (1994). Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Swedish Lymphoma Study Group. Ann Oncol 5: 809-16.
228. Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, Glabbeke M, Henry-Amar M, Carde P (2002). The achievements of the EORTC Lymphoma Group. Eur J Cancer 38 Suppl 4: 107-13.
229. Hancock SL, Tucker MA, Hoppe RT (1993). Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85: 25-31.
230. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG (1997). High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 79: 1203-10.
231. DeVita VT, Jr. (1997). Late sequelae of treatment of Hodgkin's disease. Curr Opin Oncol 9: 428-31.
232. Henry-Amar M, Joly F. (1996). Late complications after Hodgkin's disease. Ann Oncol 7 Suppl 4: 115-26.
233. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF, Jr., Boice JD, Jr., Gilbert E (2002). Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94: 182-92.
234. Amini RM, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Glimelius B (2000). Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. Eur J Haematol 65: 379-89.
235. Brandt L, Kimby E, Nygren P, Glimelius B (2001). A systematic overview of chemotherapy effects in Hodgkin's disease. Acta Oncol 40: 185-97.
236. Franklin J, Diehl V (2002). Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Ann Oncol 13: 98-101.
237. Horning SJ, Rosenberg SA, Hoppe RT (1996). Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol 7: 105-8.
238. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA (2002). Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20: 630-7.
239. Chiesi T, Federico M, Levis A, Lambertenghi Deliliers G, Gobbi PG, Santini G, Luminari S, Brugiatelli M. (2002). ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol 13: 102-106.
240. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975). Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36: 252-9.
241. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992). Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-84.
242. Klimo P, Connors JM (1985). MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3: 1174-82.
243. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P (1996). Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 14: 1421-30.
244. Dady PJ, McElwain TJ, Austin DE, Barrett A, Peckham MJ (1982). Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease. Br J Cancer 45: 851-9.
245. Diehl V, Pfreundschuh M, Loffler M, Ruhl U, Hiller E, Gerhartz H, Wilmanns W, Kirchner H, Schoppe W, Petsch S, et al. (1989). Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother 6: 155-62.
246. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H (1997). BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 8: 143-8.
247. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M (1998). BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 16: 3810-21.
248. Zittoun R, Eghbali H, Audebert A, Rojouan J, David B, Blanc CM, Hoerni B, Debray J (1987). [The combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP) before radiotherapy in localized stages of Hodgkin's disease. Phase II trials]. Bull Cancer 74: 151-7.
249. Moody AM, Pratt J, Hudson GV, Smith P, Lamont A, Williams MV (2001). British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease. Clin Oncol 13: 262-8.
250. Radford JA, Whelan JS, Rohatiner AZ, Deakin D, Harris M, Stansfeld AG, Swindell R, Wilkinson PM, James RD, Lister TA, et al. (1994). Weekly VAPEC-B chemotherapy for high grade non-Hodgkin's lymphoma: results of treatment in 184 patients. Ann Oncol 5: 147-51.
251. Radford JA, Rohatiner AZ, Ryder WD, Deakin DP, Barbui T, Lucie NP, Rossi A, Dunlop DJ, Cowan RA, Wilkinson PM, Gupta RK, James RD, Shamash J, Chang J, Crowther D, Lister TA (2002). ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 20: 2988-94.
252. Lester EP, Petroni GR, Barcos M, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, 3rd, Peterson BA (2001). Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. Cancer Invest 19: 447-58.
253. Gobbi PG, Pieresca C, Ghirardelli ML, Di Renzo N, Federico M, Merli F, Iannitto E, Pitini V, Grignani G, Donelli A, Carotenuto M, Silingardi V, Ascari E (1998). Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 91: 2704-12.
254. Ng AK, Weeks JC, Mauch PM, Kuntz KM (1999). Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. J Clin Oncol 17: 241-52.
255. Jockovich M, Mendenhall NP, Sombeck MD, Talbert JL, Copeland EM, 3rd, Bland KI (1994). Long-term complications of laparotomy in Hodgkin's disease. Ann Surg 219: 615-21; discussion 621-4.
256. Advani RH, Horning SJ (1999). Treatment of early-stage Hodgkin's disease. Semin Hematol 36: 270-81.
257. Specht L, Gray RG, Clarke MJ, Peto R (1998). Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 16: 830-43.
258. Hancock SL, Cox RS, McDougall IR (1991). Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 325: 599-605.
259. Hoppe RT (1997). Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 8: 115-8.
260. Knobel H, Havard Loge J, Brit Lund M, Forfang K, Nome O, Kaasa S (2001). Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol 19: 3226-33.
261. Horning SJ, Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D, Rosenberg SA (1997). Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15: 1736-44.
262. Brierley JD, Rathmell AJ, Gospodarowicz MK, Sutcliffe SB, Pintillie M (1997). Late relapse after treatment for clinical stage I and II Hodgkin's disease. Cancer 79: 1422-7.
263. Charlton BG, Taylor PR, Proctor SJ (1997). The PACE (population-adjusted clinical epidemiology) strategy: a new approach to multi-centred clinical research. Ojm 90: 147-51.
264. Amini RM, Glimelius B, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Enblad G (2002). A population-based study of the outcome for patients with first relapse of Hodgkin's lymphoma. Eur J Haematol 68: 225-32.
265. Peterson CG, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P (1991). Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy 21: 561-7.
266. Tai PC, Spry CJ, Peterson C, Venge P, Olsson I (1984). Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature 309: 182-4.
267. Harvima IT, Naukkarinen A, Harvima RJ, Fraki JE (1988). Immunoperoxidase and enzyme-histochemical demonstration of human skin tryptase in cutaneous mast cells in normal and mastocytoma skin. Arch Dermatol Res 280: 363-70.
268. Irani AM, Bradford TR, Kepley CL, Schechter NM, Schwartz LB (1989). Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 37: 1509-15.
269. Butterfield JH, Weiler D, Dewald G, Gleich GJ (1988). Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12: 345-55.
270. Kishi K (1985). A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res 9: 381-90.
271. Nilsson G, Blom T, Kusche-Gullberg M, Kjellen L, Butterfield JH, Sundstrom C, Nilsson K, Hellman L (1994). Phenotypic characterization of the human mast-cell line HMC-1. Scand J Immunol 39: 489-98.
272. Nilsson G, Carlsson M, Jones I, Ahlstedt S, Matsson P, Nilsson K (1994). TNF-alpha and IL-6 induce differentiation in the human basophilic leukaemia cell line KU812. Immunology 81: 73-8.
273. Nilsson G, Blom T, Harvima I, Kusche-Gullberg M, Nilsson K, Hellman L (1996). Stem cell factor-dependent human cord blood derived mast cells express alpha- and beta-tryptase, heparin and chondroitin sulphate. Immunology 88: 308-14.
274. Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, Matsumoto K, Iikura Y, Awaji T, Tsujimoto G, Yanagida M, Uzumaki H, Takahashi G, Tsuji K, Nakahata T (1996). Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 157: 343-50.
275. Nilsson K, Sundstrom C (1974). Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. Int J Cancer 13: 808-23.
276. Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J (1986). Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res 10: 487-500.
277. Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, Gerdes J, Boie C (1981). Hodgkin's disease: establishment and characterization of four in vitro cell lines. J Cancer Res Clin Oncol 101: 111-24.
278. Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, Miwa H, Shirakawa S, Hatanaka M, Honjo T (1986). Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 68: 285-92.
279. Poppema S, De Jong B, Atmosoerodjo J, Idenburg V, Visser L, De Ley L (1985). Morphologic, immunologic, enzymehistochemical and chromosomal analysis of a cell line derived from Hodgkin's disease. Evidence for a B-cell origin of Sternberg-Reed cells. Cancer 55: 683-90.
280. Young JD, Liu CC, Butler G, Cohn ZA, Galli SJ (1987). Identification, purification, and characterization of a mast cell- associated cytolytic factor related to tumor necrosis factor. Proc Natl Acad Sci U S A 84: 9175-9.
281. Arora N, Min KU, Costa JJ, Rhim JS, Metcalfe DD (1993). Immortalization of mouse bone marrow-derived mast cells with Ad12-SV40 virus. Int Arch Allergy Immunol 100: 319-27.
282. Dunn T, Potter, M. (1957). A transplantable mast-cell neoplasm in the mouse. Journal of the National Cancer Institute 18: 587-601.
283. Bystrom J, Tenno T, Hakansson L, Amin K, Trulson A, Hogbom E, Venge P (2001). Monocytes, but not macrophages, produce the eosinophil cationic protein. Apmis 109: 507-16.
284. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD (1995). The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 96: 2702-10.
285. Lowe D, Jorizzo J, Hutt MS (1981). Tumour-associated eosinophilia: a review. J Clin Pathol 34: 1343-8.
286. Pastrnak A, Jansa P (1984). Local eosinophilia in stroma of tumors related to prognosis. Neoplasma 31: 323-6.
287. Colby TV, Hoppe RT, Warnke RA (1982). Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer 49: 1848-58.
288. d'Amore ES, Lee CK, Aeppli DM, Levitt SH, Frizzera G (1992). Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type. A study of 123 patients with limited stage disease who had undergone laparotomy and were treated with radiation therapy. Arch Pathol Lab Med 116: 856-61.
289. vGruss HJ, DaSilva N, Hu ZB, Uphoff CC, Goodwin RG, Drexler HG (1994). Expression and regulation of CD30 ligand and CD30 in human leukemia- lymphoma cell lines. Leukemia 8: 2083-94.
290. Fuggle W, Crocker J, Smith PJ. (1984). A quantitative study of eosinophil polymorphs in Hodgkin's disease. J Clin Pathol 37: 267-71.
291. Zhang J, Rosenberg HF (2000). Sequence variation at two eosinophil-associated ribonuclease loci in humans. Genetics 156: 1949-58.
292. Jonsson UB, Bystrom J, Stalenheim G, Venge P (2002). Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy 32: 1092-5.
293. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, et al. (1993). CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73: 1349-60.
294. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, Patterson B, Snow BE, Mak TW (2001). Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97: 250-5.
295. Glossmann JP, Josting A, Diehl V (2002). New treatments for Hodgkin's Disease. Curr Treat Options Oncol 3: 283-90.
296. Zittoun R, Audebert A, Hoerni B, Bernadou A, Krulik M, Rojouan J, Eghbali H, Merle-Beral H, Parlier Y, Diebold J, et al. (1985). Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 3: 207-14.
297. Bonfante V, Viviani, S, Devizzi, L et al. (2001). Ten-years experience with ABVD plus radiotherapy: Subtotal nodal (STNI) vs involved-field (IFRT) in early stage Hodgkin's disease. Proc Am Soc Clin Oncol. 20: 281a (Abstr 1120).
298. Engert A, Schiller, P, Pfistner, B et al. (2001). Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients with intermediate-stage HD. Blood 98: 768 (Abstr 3199).
299. Vlachaki MT, Hagemeister FB, Fuller LM, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD (1997). Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. Int J Radiat Oncol Biol Phys 38: 593-9.
300. Mauch PM (1996). Management of early stage Hodgkin's disease: the role of radiation therapy and/or chemotherapy. Baillieres Clin Haematol 9: 531-41.
301. Enblad G, Glimelius B, Sundstrom C (1991). Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study. Ann Oncol 2: 297-302.